ABOUT KALOCYTE
KaloCyte, Inc., a pre-clinical stage healthcare biotech startup company, is located in Baltimore as a UM BioPark Affiliate. KaloCyte’s headquarters is located at Connect Labs at 4MLK, with labs sited within the UM School of Medicine’s Center for Blood Oxygen Transport and Hemostasis (CBOTH) directed by Allan Doctor, MD (KaloCyte Co-Founder and CSO). KaloCyte was incorporated in 2016 by co-founders Dr. Doctor, Dipanjan Pan, PhD and Phil Spinella, MD – expert researchers in physiology, bioengineering, and trauma care. KaloCyte has demonstrated pre-clinical safety and efficacy for ErythroMer, a dried, shelf-stable artificial red blood cell envisioned for use when stored red blood cells are not available. KaloCyte is supported by $19M in DARPA, NIH and DOD grants and over $8M in investor funding (cumulative to date).
KaloCyte History
2026
- Lab and office expansion to Connect Labs at 4MLK
- Qualified Maryland Biotech Company (QMBC) for State Biotech Investment Initiative Tax Credit (BIITC)
2025
- Raised $2.6M, first half of $5M seed equity round led by Ferocity Capital
- Awarded DARPA SBIR ($1.8M) for production of materials for IND-enabling studies
- Selected as an awardee of the BLUE KNIGHT™ Resident QuickFire Challenge ($250K): Promoting Pivotal Progress
- Exclusive licensing agreement with Chrysea for biosynthetic hemoglobin production
- Selected to join BLUE KNIGHT™
- Featured in The New Yorker: The Long Quest for Artificial Blood
- Qualified Maryland Biotech Company (QMBC) for State Biotech Investment Initiative Tax Credit (BIITC)
- Subcontract for DARPA FSHARP renewed for Year 3
- Team expanded to 12 employees
2024
- Featured in Science: The ultimate blood substitute? The U.S. military is betting $46 million on it / Science / AAAS
- Raised additional $0.7M of bridge round
- Team expanded to 10 employees, plus one intern
- Awarded DoD CMRP TTDA grant ($2.5M) for lyophilization optimization
- Subcontract for DARPA FSHARP expanded by $500K
- Maryland Tech Council ICON Awards finalist – Emerging Life Science CEO of the Year
- Qualified Maryland Biotech Company (QMBC) for State Biotech Investment Initiative Tax Credit (BIITC)
2023
- Opened new bridge round, raised $1M
- Grew team to 9 employees, plus one intern
- Awarded NIH Phase 2B grant ($3M) for IND-enabling toxicology studies
- Subcontract for DARPA FSHARP $46M consortium award to UMB ($3.2M to KaloCyte)
- Comcast RISE Award recipient
- Maryland Tech Council ICON Awards finalist – Emerging Life Science Company of the Year
- Qualified Maryland Biotech Company (QMBC) for State Biotech Investment Initiative Tax Credit (BIITC)
- Finalist in the 8th Annual Biohealth Capital Region’s Crab Trap Pitch Event
2022
- Raised $1M convertible note
- Expanded space, scientific team and expertise (total 8 employees); hosted first intern from UM School of Pharmacy (UM-SOP)
- Entered national phase with EM V2 patent filings in 11 target countries/regions
- Filed joint IP with UM for EM clearance system
- Awarded Maryland Industrial Partnerships (MIPS) Phase 2 grant ($100K) with UM-SOM
- Angel Capital Association Summit – Innovation Funders Showcase winner
- PitchForce A-Round – First Place winner
2021
- Raised $1M convertible note
- Expanded scientific team with 2 new scientists (total 5 employees)
- Awarded NIH CRP SB1 grant ($500K)
- Filed and published EM V2 patent (US and PCT)
- Held Pre-IND Meeting with FDA CBER
- Awarded Maryland Industrial Partnerships (MIPS) Phase 1 grant ($100K) with UM-SOM
2020
- Raised $1M convertible note
- Filed provisional patent application for lead candidate, EM V2
2019
- Moved to Baltimore, MD as a University of Maryland (UM) BioPark Affiliate
- Leased lab and office space in new Center for Blood Oxygen Transport & Hemostasis (CBOTH) at UM School of Medicine (UM-SOM)
- Awarded NIH Ph1 SBIR grant ($375K)
- Subaward on Haima Therapeutics’ DoD CDMRP CRRP grant ($1.6M)
- Participated in NIH CAP accelerator program
- Held INTERACT Meeting with FDA
2018
- First seed funding ($800K) equity
- Board of Directors expanded
- First scientists hired
- CEO recruited
- Startup Connection Event: Rubin Brown Award
2017
- American Society Hematology (ASH), awarded “Best of ASH” & press release
- Awarded NIH NHLBI Fast Track STTR grant ($2M)
- Awarded DoD CDMRP grant ($3M)
2016
- KaloCyte, Inc. formed as a Delaware C-Corporation
- Patents issued, ‘Quick Start License’ with WUSTL
- Board of Directors and Scientific Advisory Board form
2010-2015
by Drs. Pan, Doctor & Spinella
at Washington University in St. Louis (WUSTL)
- Bench Pilot Work
Formulation demonstrates key requirements
Novel transfusion models - First in vivo POC
Efficacy for hemorrhagic shock and 70% blood exchange
Formulation ErythroMer (EM) V1 - First Funding & Support
Children’s Discovery Institute OAIF Grant ($1M)
Invention Disclosure (WUSTL)
Bear Cub award ($75K) - Incubator Program: BioGenerator Fundamentals
CONTACT US
KaloCyte, Inc.
4 N. Martin Luther King Jr. Blvd
Suite 300
Baltimore, MD 21201
QUICK LINKS
ABOUT US
KaloCyte was founded by a distinguished team of researchers in physiology, bioengineering, and trauma care and is poised to deliver ErythroMer, a dried, bio-inspired artificial red blood cell, to market. ErythroMer is envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by over $20M in federal grants and investor funding.